# Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

> **NCT06299319** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Centre for Addiction and Mental Health** · enrollment: 10 (estimated)

## Conditions studied

- Obsessive-Compulsive Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT06299319
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299319, "Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06299319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*